MYGN
MYRIAD GENETICS INC
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$3.89
−6.04%0
Insider buys (3m)
0
Insider sells (3m)
$0.00
Net value (3m)
-10.3%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Sep 17, 2026 | Sikri Vishal · officer: EVP, Commercial | A-Award | 257,731 | $0.00 |
| Sep 8, 2026 | Fox Jennifer Lynne · officer: Chief Legal Officer | F-InKind | 4,398 | $3.23 |
| Aug 17, 2026 | Wheeler Benjamin Richard · officer: Chief Financial Officer | F-InKind | 8,761 | $3.03 |
| Jun 12, 2026 | Donnelly Brian J · officer: Chief Commerical Officer | A-Award | 5,000 | $3.94 |
| Jun 12, 2026 | Raha Samraat S. · director, officer: President and CEO | A-Award | 3,542 | $3.94 |
| Jun 9, 2026 | Kumar Rashmi · director | Sale | 15,000 | $4.46 |
| Jun 5, 2026 | Newcomer Lee Nisley · director | A-Award | 59,701 | $0.00 |
| Jun 5, 2026 | Bisaro Paul · director | A-Award | 59,701 | $0.00 |
| Jun 5, 2026 | Skovronsky Daniel · director | A-Award | 59,701 | $0.00 |
| Jun 5, 2026 | Phanstiel S. Louise · director | A-Award | 59,701 | $0.00 |
| Jun 5, 2026 | Dreismann Heinrich · director | A-Award | 59,701 | $0.00 |
| Jun 5, 2026 | Davis Mark Steven · director | A-Award | 59,701 | $0.00 |
| Jun 5, 2026 | Kumar Rashmi · director | A-Award | 59,701 | $0.00 |
| Jun 5, 2026 | Reitan Colleen F · director | A-Award | 59,701 | $0.00 |
| Jun 2, 2026 | Jampa Raj · officer: Chief Technology Officer | A-Award | 251,889 | $0.00 |
| May 14, 2026 | Bisaro Paul · director | Purchase | 7,500 | $3.69 |
| May 4, 2026 | Donnelly Brian J · officer: Chief Commerical Officer | F-InKind | 55,975 | $4.80 |
| Apr 15, 2026 | Verratti Mark · officer: Chief Operating Officer | F-InKind | 1,069 | $4.91 |
| Apr 15, 2026 | Muzzey Dale · officer: Chief Scientific Officer | F-InKind | 946 | $4.91 |
| Mar 23, 2026 | Muzzey Dale · officer: Chief Scientific Officer | F-InKind | 2,019 | $4.58 |
| Mar 23, 2026 | Verratti Mark · officer: Chief Operating Officer | F-InKind | 2,055 | $4.58 |
| Mar 23, 2026 | Wheeler Benjamin Richard · officer: Chief Financial Officer | F-InKind | 549 | $4.58 |
| Mar 16, 2026 | Muzzey Dale · officer: Chief Scientific Officer | F-InKind | 8,288 | $4.66 |
| Mar 16, 2026 | Verratti Mark · officer: Chief Operating Officer | F-InKind | 5,611 | $4.66 |
| Mar 16, 2026 | Muzzey Dale · officer: Chief Scientific Officer | A-Award | 173,196 | $0.00 |
| Mar 16, 2026 | Haas Kevin Richard · officer: Chief Technology Officer | F-InKind | 4,161 | $4.66 |
| Mar 16, 2026 | Verratti Mark · officer: Chief Operating Officer | A-Award | 247,423 | $0.00 |
| Mar 16, 2026 | Raha Samraat S. · director, officer: President and CEO | F-InKind | 36,304 | $4.66 |
| Mar 16, 2026 | Raha Samraat S. · director, officer: President and CEO | F-InKind | 10,816 | $4.66 |
| Mar 16, 2026 | Verratti Mark · officer: Chief Operating Officer | F-InKind | 9,096 | $4.66 |
Institutional positioning
13F filings over the trailing two quarters
New 77Increased 150Reduced 128Sold out 48
| Filer | Action | Shares | Filed |
|---|---|---|---|
| ORBIMED ADVISORS LLC | New Position | 125,000,000 | May 15, 2026 |
| BlackRock, Inc. | Increased | 10,890,440 | Aug 7, 2026 |
| BLACKROCK, INC. | Reduced | 8,889,644 | May 13, 2026 |
| MILLENNIUM MANAGEMENT LLC | Reduced | 6,668,817 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | Reduced | 6,620,372 | Aug 14, 2026 |
| Vestal Point Capital, LP | Increased | 5,735,000 | Aug 14, 2026 |
| GLENVIEW CAPITAL MANAGEMENT, LLC | Increased | 5,411,978 | May 15, 2026 |
| STATE STREET CORP | Increased | 4,985,060 | Aug 7, 2026 |
| D. E. Shaw & Co., Inc. | Increased | 4,582,083 | Aug 14, 2026 |
| D. E. SHAW & CO., INC. | Reduced | 4,499,724 | May 15, 2026 |
| STATE STREET CORP | Reduced | 4,424,027 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | Increased | 4,081,376 | Aug 13, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 3,924,525 | May 15, 2026 |
| MORGAN STANLEY | Reduced | 3,168,742 | May 15, 2026 |
| ACADIAN ASSET MANAGEMENT LLC | Increased | 3,126,973 | Aug 13, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Sep 17, 2026